Drug Trial Radar · NCT01851707
A Double-Blind Study Evaluating Duvelisib in Subjects With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone
Last checked: Nov 19, 2026Latest source record: Mar 17, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
322
Actual
Start
Apr 2013
Primary completion
Dec 2014
Study completion Feb 2015
Sponsor
- Lead sponsor
- SecuraBioIndustry
- Sponsor type
- Industry
- First posted
- May 10, 2013
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to investigate the safety and efficacy of multiple dose levels of the investigational product (study drug), IPI-145, in combination with methotrexate compared to methotrexate alone in subjects with active moderate-to-severe Rheumatoid Arthritis.
Conditions
- Rheumatoid Arthritis
Interventions
IPI-145Drug
2 blinded capsules will be administered twice a day (morning and night) for 12 weeks.
PlaceboDrug
2 blinded capsules will be administered twice a day (morning and night) for 12 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of subjects who achieve a 20% improvement in the American College of Rheumatology Criteria (ACR20) from Baseline to Week 12Time frame: Baseline (Day 1), Weeks 2, 4, 6, 8, 10 and 12
Locations
64 sites in 11 countries. Site status is shown where the registry gives one.
Site not named
Pleven, Bulgaria
Site not named
Plovdiv, Bulgaria
Site not named
Rousse, Bulgaria
Site not named
Sofia, Bulgaria
Site not named
Stara Zagora, Bulgaria
Site not named
Targovishte, Bulgaria
Site not named
Varna, Bulgaria
Site not named
Medellín, Antioquia, Colombia
Site not named
Bogota, Cundinamarca, Colombia
Site not named
Bucaramanga, Santander Department, Colombia
Site not named
Frankfurt, Germany
Site not named
Halle, Germany
Site not named
Budapest, Hungary
Site not named
Kecskemét, Hungary
Site not named
Mezőkövesd, Hungary
Site not named
Nyíregyháza, Hungary
Site not named
Veszprém, Hungary
Site not named
Mexico City, Mexico
Site not named
Mexico City, Col Roam Sur, Mexico
Site not named
Mexico City, Del Cuautemoc, Mexico
Site not named
León, Guanajuato, Mexico
Site not named
Guadalajara, Jalisco, Mexico
Site not named
Madero, Mexico DF, Mexico
Site not named
Morelia, Michoacán, Mexico
Site not named
Monterrey, Nuevo León, Mexico
Site not named
San Luis Potosí City, San Luis Potosi, C.P., Mexico
Site not named
Mérida, Yucatán, Mexico
Site not named
Wellington, New Zealand
Site not named
Otahuhu, Auckland, New Zealand
Site not named
Bialystok, Poland
Site not named
Elblag, Poland
Site not named
Krakow, Poland
Site not named
Lublin, Poland
Site not named
Nadarzyn, Poland
Site not named
Poznan, Poland
Site not named
Skierniewice, Poland
Site not named
Sosnowiec, Poland
Site not named
Stalowa Wola, Poland
Site not named
Starachowice, Poland
Site not named
Wroclaw, Poland
Showing 40 of 64 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.